Global Sanger Sequencing Market, By Application (Diagnostics, Biomarkers and Cancer, Reproductive Health, Personalized Medicine, Forensics, Others), Sequencing (Shotgun Sequencing, Targeted Gene Sequencing, Others), Laboratory (Wet Labs, Dry Labs), Research (In-House, Outsourced), End Use (Academic and Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Hospitals and Clinics) – Industry Trends and Forecast to 2030.
Sanger Sequencing Market Analysis and Size
In recent years, Sanger sequencing is renowned for its accuracy and reliability in obtaining high-quality DNA sequencing data. However, Sanger sequencing is typically limited in terms of the number of samples that can be processed simultaneously. In addition, Sanger sequencing, with its ability to accurately sequence specific genes or regions of interest, plays a crucial role in diagnostic testing, identifying disease-causing mutations, and monitoring treatment response. The growing adoption of clinical genomics offers opportunities for the Sanger sequencing market. Although, obtaining regulatory approvals and reimbursement coverage for Sanger sequencing-based tests can be challenging, requiring time and resources to navigate the regulatory environment which acts as a challenge for the growth of the market.
Data Bridge Market Research analyses that the Sanger Sequencing market which was USD 2.275.20 million in 2022, is likely to reach to USD 8,846.40 million by 2030, and is expected to undergo a CAGR of 18.50% during the forecast period. “Diagnostics” dominates the application segment of the Sanger Sequencing market owing to the growing demand for better methods of diagnosis and testing in patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Application (Diagnostics, Biomarkers and Cancer, Reproductive Health, Personalized Medicine, Forensics, and Others), Sequencing (Shotgun Sequencing, Targeted Gene Sequencing, Others), Laboratory (Wet Labs, Dry Labs), Research (In-House, Outsourced), End Use (Academic and Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Hospitals and Clinics)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc (U.S.), Source BioScience (U.K.), GenScript (U.S.), LGC Limited (U.K.), CeMIA (U.S.), Quintara Biosciences (U.S.), GenHunter Corporation (U.S.), GENEWIZ (U.S.), Nucleics (U.K.), SciGenom Labs Pvt. Ltd (India), Microsynth AG (Switzerland), Eurofins Scientific (Luxembourg), LGC Limited (U.K.), Fasteris SA (Switzerland), and StarSEQ GmbH (Germany)
|
|
Market Opportunities
|
|
Market Definition
The Sanger technique of DNA sequencing relies on the random incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication and uses electrophoresis. However, for smaller-scale initiatives and for validating the outcomes of deep sequencing, the Sanger approach is still widely used. It can still create DNA sequence reads of more than 500 nucleotides and maintain accuracy levels around 99.99 percent, giving it an edge over short-read sequencing methods (like Illumina).
Global Sanger Sequencing Market Dynamics
Drivers
- Technological advancements
The market for Sanger's sequencing services is expanding due to technological developments in sequencing methods, benefits of Sanger's sequencing, and an increase in genome mapping initiatives. In addition, sequencing applications and R&D expenditure boost have added to the market's expansion.
- Research and development (R&D) activities
The increased attention that vendors are paying to developing economies like China, India, and Southeast Asia is anticipated to promote market expansion. The market is expected to experience significant growth in the near future as a result of rising R&D spending and a boom in Sanger sequencing applications.
- Rise in genetic illness
The expanding use of genetic testing on vertebrates and plants, other factors influencing the market's growth include the rising prevalence and familiarity of genetic illnesses and tailored medicine.
Opportunities
- Research and development in genomics
The field of genomics is continuously evolving, with ongoing research and development efforts in areas such as cancer genomics, rare genetic disorders, and infectious diseases. Sanger sequencing is a valuable tool for researchers to validate and confirm genetic variants discovered through next-generation sequencing technologies. The demand for Sanger sequencing in research and development activities presents opportunities for market growth.
- Increasing demand for personalized medicine
With advancements in genomic research and personalized medicine, there is a growing need for accurate and reliable genetic sequencing technologies like Sanger sequencing. This market opportunity arises from the increasing demand for genomic testing to guide personalized treatment plans for various diseases.
Restraints/Challenges
- Competition from next-generation sequencing (NGS) technologies
NGS technologies have revolutionized genetic sequencing by enabling high-throughput sequencing of entire genomes or exomes at a lower cost per base. As a result, the Sanger sequencing market faces competition from NGS platforms, which offer broader applications and higher throughput capabilities.
- Targeted sequencing limitations
Sanger sequencing is well-suited for targeted sequencing of specific genes or regions of interest. However, it may not be as suitable for whole-genome or exome sequencing due to its limited throughput and higher cost per base. This can restrict its application in certain research or clinical settings.
This Sanger sequencing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Sanger Sequencing market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Development
- In June 2020, The FDA recently granted Illumina the Emergency Use Authorization (EUA) for its COVIDSeq Test, which is designed to sequence the entire genome of the brand-new SARS-CoV-2 virus. This test can handle more than 3,000 samples with the use of Illumina's high-throughput NovaSeq 6000 technology, and findings are available in 24 hours.
Global Sanger Sequencing Market Scope
The Sanger sequencing market is segmented on the basis of application, sequencing, laboratory, research, and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Application
- Diagnostics
- Biomarkers and Cancer
- Reproductive Health
- Personalized Medicine
- Forensics
- Others
Sequencing
- Shotgun Sequencing
- Targeted Gene Sequencing
- Others
Laboratory
- Wet Labs
- Dry Labs
Research
- In-House
- Outsourced
End Use
- Academic
- Government Research Institutes
- Pharmaceutical Companies
- Biotechnology Companies
- Hospitals
- Clinics
Global Sanger Sequencing Market Regional Analysis/Insights
The global Sanger sequencing market is analyzed and market size insights and trends are provided by country, application, sequencing, laboratory, research, and end use as referenced above.
The countries covered in the Sanger Sequencing market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.
North America is expected to dominate the Sanger sequencing market because of the rising number of geriatric population and innovative medical technology adoption.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to an expansion in research and development expenditure and a rise in the utilization of Sanger sequencing.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The Sanger sequencing market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the Sanger sequencing market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the Sanger sequencing market.
Competitive Landscape and Sanger Sequencing Market Share Analysis
The Sanger sequencing market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the Sanger sequencing market.
Some of the major players operating in the Sanger Sequencing market are:
- Thermo Fisher Scientific Inc (U.S.)
- Source BioScience (U.K.)
- GenScript (U.S.)
- LGC Limited (U.K.)
- CeMIA (U.S.),
- Quintara Biosciences (U.S.)
- GenHunter Corporation (U.S.)
- GENEWIZ (U.S.), Nucleics (U.K.)
- SciGenom Labs Pvt. Ltd (India)
- Microsynth AG (Switzerland)
- Eurofins Scientific (Luxembourg)
- LGC Limited (U.K.)
- Fasteris SA (Switzerland)
- StarSEQ GmbH (Germany)
SKU-